235 related articles for article (PubMed ID: 35850450)
21. Management of Hypertriglyceridemia: Common Questions and Answers.
Oh RC; Trivette ET; Westerfield KL
Am Fam Physician; 2020 Sep; 102(6):347-354. PubMed ID: 32931217
[TBL] [Abstract][Full Text] [Related]
22. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction.
Boden WE; Baum S; Toth PP; Fazio S; Bhatt DL
Future Cardiol; 2021 Jan; 17(1):155-174. PubMed ID: 32959713
[TBL] [Abstract][Full Text] [Related]
23. Childhood Hypertriglyceridemia: Is It Time for a New Approach?
Sunil B; Ashraf AP
Curr Atheroscler Rep; 2022 Apr; 24(4):265-275. PubMed ID: 35107763
[TBL] [Abstract][Full Text] [Related]
24. Approach to the Patient With Moderate Hypertriglyceridemia.
Subramanian S
J Clin Endocrinol Metab; 2022 May; 107(6):1686-1697. PubMed ID: 35184196
[TBL] [Abstract][Full Text] [Related]
25. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
[TBL] [Abstract][Full Text] [Related]
26. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
Orringer CE; Jacobson TA; Maki KC
J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
[TBL] [Abstract][Full Text] [Related]
27. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.
Spagnuolo CM; Hegele RA
Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828
[TBL] [Abstract][Full Text] [Related]
29. Management of hypertriglyceridemia in the diabetic patient.
Jialal I; Amess W; Kaur M
Curr Diab Rep; 2010 Aug; 10(4):316-20. PubMed ID: 20532703
[TBL] [Abstract][Full Text] [Related]
30. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR
Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351
[TBL] [Abstract][Full Text] [Related]
31. Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
Kayıkçıoğlu M; Shahbazova S; İbrahimov F; Can LH
Turk Kardiyol Dern Ars; 2020 Jun; 48(4):359-367. PubMed ID: 32519982
[TBL] [Abstract][Full Text] [Related]
32. A More Atherogenic Lipoprotein Status Is Present in Adults With Type 2 Diabetes Mellitus Than in Those Without With Equivalent Degrees of Hypertriglyceridemia.
Sun CJ; Brisson D; Sharma R; Birkett N; Gaudet D; Ooi TC
Can J Diabetes; 2022 Jul; 46(5):480-486. PubMed ID: 35718690
[TBL] [Abstract][Full Text] [Related]
33. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
34. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.
Hussain A; Ballantyne CM; Saeed A; Virani SS
Curr Atheroscler Rep; 2020 Jun; 22(7):25. PubMed ID: 32494924
[TBL] [Abstract][Full Text] [Related]
35. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
36. Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction.
Zambon A; Pirillo A; Zambon S; Norata GD; Catapano AL
Curr Atheroscler Rep; 2020 Oct; 22(12):74. PubMed ID: 33009961
[TBL] [Abstract][Full Text] [Related]
37. Investigational drugs in development for hypertriglyceridemia: a coming-of-age story.
Rhainds D; Brodeur MR; Tardif JC
Expert Opin Investig Drugs; 2019 Dec; 28(12):1059-1079. PubMed ID: 31752565
[No Abstract] [Full Text] [Related]
38. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
39. Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia.
Mszar R; Bart S; Sakers A; Soffer D; Karalis DG
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835917
[TBL] [Abstract][Full Text] [Related]
40. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey.
Fan W; Philip S; Granowitz C; Toth PP; Wong ND
J Clin Lipidol; 2019; 13(1):100-108. PubMed ID: 30594443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
